VYTRUS BIOTECH EO -01 Total Assets
VYTRUS BIOTECH EO -01 total assets. Based on the latest financial reports, VYTRUS BIOTECH EO -01 (V5P) holds total assets worth €14.66 Million EUR (≈ $17.14 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see V5P market cap overview for the company's overall valuation and market capitalisation.
Total Assets of VYTRUS BIOTECH EO -01 (2021–2025)
Total assets of VYTRUS BIOTECH EO -01 from 2021 to 2025. This chart illustrates how VYTRUS BIOTECH EO -01's total assets have evolved over time, based on quarterly financial data. See VYTRUS BIOTECH EO -01 share price for real-time trading data and today's change.
VYTRUS BIOTECH EO -01 - Asset Composition Analysis
VYTRUS BIOTECH EO -01 Total Assets Breakdown (December 2025)
VYTRUS BIOTECH EO -01 total assets breakdown as of December 2025. VYTRUS BIOTECH EO -01's total assets of €14.66 Million consist of 36.8% current assets and 63.2% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 23.0% |
| Accounts Receivable | €982.01K | 6.7% |
| Inventory | €623.02K | 4.3% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €4.96 Million | 33.8% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how VYTRUS BIOTECH EO -01's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore VYTRUS BIOTECH EO -01 (V5P) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: VYTRUS BIOTECH EO -01's current assets represent 36.8% of total assets in 2025, an increase from 25.3% in 2021.
- Cash Position: Cash and equivalents constituted 23.0% of total assets in 2025, up from 17.9% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 33.0% of total assets, a decrease from 39.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 33.8% of total assets.
VYTRUS BIOTECH EO -01 Competitors by Total Assets
Key competitors of VYTRUS BIOTECH EO -01 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL LTD SPON.ADR 2
F:CSJA
|
Germany | €38.45 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €301.45 Million |
|
NANOBIOTIX S.A. SP.ADR
F:5NRA
|
Germany | €67.76 Million |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513
|
China | CN¥3.82 Billion |
VYTRUS BIOTECH EO -01 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.03 | 3.03 | 3.28 |
| Quick Ratio | 2.68 | 2.61 | 2.81 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €3.61 Million | €2.54 Million | €2.46 Million |
VYTRUS BIOTECH EO -01 - Advanced Valuation Insights
This section examines the relationship between VYTRUS BIOTECH EO -01's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 12.47 |
| Latest Market Cap to Assets Ratio | 8.57 |
| Asset Growth Rate (YoY) | 31.7% |
| Total Assets | €14.66 Million |
| Market Capitalization | $125.66 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values VYTRUS BIOTECH EO -01's assets at a significant premium (8.57x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: VYTRUS BIOTECH EO -01's assets grew by 31.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for VYTRUS BIOTECH EO -01 (2021–2025)
The table below shows the annual total assets of VYTRUS BIOTECH EO -01 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €14.66 Million ≈ $17.14 Million |
+31.72% |
| 2024-12-31 | €11.13 Million ≈ $13.01 Million |
+19.50% |
| 2023-12-31 | €9.31 Million ≈ $10.89 Million |
+16.38% |
| 2022-12-31 | €8.00 Million ≈ $9.36 Million |
+11.43% |
| 2021-12-31 | €7.18 Million ≈ $8.40 Million |
-- |
About VYTRUS BIOTECH EO -01
Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. It offers Clarivine that activates skin's regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Capilia Lon… Read more